A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial
Kanagaratnam P, Francis D, Chamie D, Coyle C, Marynina A, Katritsis G, Paiva P, Szigeti M, Cole G, de Andrade Nunes D, Howard J, Esper R, Khan M, More R, Barreto G, Meneguz-Moreno R, Arnold A, Nowbar A, Kaura A, Mariveles M, March K, Shah J, Nijjer S, Lip G, Mills N, Camm A, Cooke G, Corbett S, Llewelyn M, Ghanima W, Toshner M, Peters N, Petraco R, Al-Lamee R, Boshoff A, Durkina M, Malik I, Ruparelia N, Cornelius V, Shun-Shin M. A randomized controlled trial to investigate the use of acute coronary syndrome therapy in patients hospitalized with COVID-19: the COVID-19 Acute Coronary Syndrome trial. Journal Of Thrombosis And Haemostasis 2023, 21: 2213-2222. PMID: 37230416, PMCID: PMC10204350, DOI: 10.1016/j.jtha.2023.04.045.Peer-Reviewed Original ResearchConceptsCoronary disease risk factorsIntervention arm participantsAcute coronary syndrome trialsRisk factorsDisease risk factorsLength of hospital stayLow-dose rivaroxabanAcute coronary syndrome therapyOpen-label trialCoronary artery diseaseRandomized Controlled TrialsAcute hospitalsArm participantsPrimary efficacyStandard careNo significant differenceMedian timeThrombotic complicationsTreatment regimenHospital staySyndrome therapyPoor outcomeClinical statusSecondary outcomesArtery disease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply